Bordeaux Wealth Advisors LLC Boosts Holdings in Merck & Co., Inc. (NYSE:MRK)

Bordeaux Wealth Advisors LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 76.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,573 shares of the company’s stock after acquiring an additional 1,981 shares during the period. Bordeaux Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $499,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Bare Financial Services Inc purchased a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. purchased a new position in Merck & Co., Inc. during the 4th quarter valued at $30,000. RIA Advisory Group LLC bought a new position in Merck & Co., Inc. in the 4th quarter valued at $30,000. Ruedi Wealth Management Inc. increased its stake in Merck & Co., Inc. by 180.2% in the third quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the period. Finally, AlphaMark Advisors LLC bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth $34,000. Institutional investors own 76.07% of the company’s stock.

Insider Activity

In related news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the transaction, the insider now owns 19,569 shares in the company, valued at approximately $2,443,972.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.09% of the company’s stock.

Analyst Upgrades and Downgrades

MRK has been the topic of several recent analyst reports. Barclays raised their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, April 18th. Berenberg Bank increased their price objective on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. StockNews.com upgraded Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Finally, TD Cowen upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $125.00 to $135.00 in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $131.33.

Merck & Co., Inc. Stock Down 0.6 %

NYSE MRK traded down $0.75 during trading on Friday, hitting $127.51. The company’s stock had a trading volume of 6,218,206 shares, compared to its average volume of 8,239,238. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10. The company has a market cap of $322.99 billion, a PE ratio of 141.68, a P/E/G ratio of 1.65 and a beta of 0.39. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. The business’s 50 day simple moving average is $126.49 and its 200-day simple moving average is $116.58.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.15%. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. During the same period last year, the business earned $1.40 EPS. Merck & Co., Inc.’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities analysts anticipate that Merck & Co., Inc. will post 8.69 EPS for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.